In a randomized phase 2 safety trial for patients with moderate-to-severe ARDS, Matthay et al. revealed a decrease in endothelial injury ascertained by reduced plasma concentrations of ANGPT2 in the MSC-treated patients versus the control group27. The gene discussed is ANGPT2; the disease is acute respiratory distress syndrome.